|
注册号: Registration number: |
ChiCTR2400087718 |
|
最近更新日期: Date of Last Refreshed on: |
2024-08-02 09:08:25 |
|
注册时间: Date of Registration: |
2024-08-02 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
穴位埋线治疗围绝经期中心性肥胖的疗效观察和优势研究 |
|
Public title: |
Efficacy and advantages of acupoint catgut embedding in the treatment of perimenopausal central obesity |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
超声引导穴位埋线治疗围绝经期中心性肥胖的疗效观察和优势研究 |
|
Scientific title: |
Efficacy and advantages of ultrasound-guided acupoint catgut embedding in the treatment of perimenopausal central obesity |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
金园园 |
研究负责人: |
金园园 |
|
Applicant: |
Yuanyuan Jin |
Study leader: |
Yuanyuan Jin |
|
申请注册联系人电话: Applicant telephone: |
+86 130 7182 2110 |
研究负责人电话:
Study leader's |
+86 130 7182 2110 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
jinghuo1606@126.com |
研究负责人电子邮件: Study leader's E-mail: |
jinghuo1606@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
浙江杭州西湖区古墩路1229号浙江医院针灸科 |
研究负责人通讯地址: |
浙江杭州西湖区古墩路1229号浙江医院针灸科 |
|
Applicant address: |
Department of Acupuncture and Moxibustion, Zhejiang Hospital, 1229 Gudun Road, Xihu District, Hangzhou, Zhejiang |
Study leader's address: |
Department of Acupuncture and Moxibustion, Zhejiang Hospital, 1229 Gudun Road, Xihu District, Hangzhou, Zhejiang |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
浙江医院 |
||
|
Applicant's institution: |
Zhejiang Hospital |
||
|
研究负责人所在单位: |
浙江医院 |
||
|
Affiliation of the Leader: |
Zhejiang Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2021临审第(129K)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
浙江医院伦理审查委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Zhejiang Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-11-15 00:00:00 | ||
|
伦理委员会联系人: |
李卫 |
||
|
Contact Name of the ethic committee: |
Wei Li |
||
|
伦理委员会联系地址: |
浙江省杭州市灵隐路12号 |
||
|
Contact Address of the ethic committee: |
12 Lingyin Road, Hangzhou City, Zhejiang Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 571 8159 5231 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
浙江医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Zhejiang Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
浙江杭州西湖区古墩路1229号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1229 Gudun Road, Xihu District, Hangzhou, Zhejiang |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
浙江省中医药管理局 |
||||||||||||||||||||||
|
Source(s) of funding: |
Zhejiang Administration of traditional Chinese Medicine |
||||||||||||||||||||||
|
研究疾病: |
围绝经期中心性肥胖 |
||||||||||||||||||||||
|
Target disease: |
Perimenopausal central obesity |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
采用穴位埋线干预围绝经期中心性肥胖女性,以假埋线+生活方式干预组为对照,观察治疗前后的体重、体重指数、腰围、臀围、腰臀比、腰高比,相关血液指标以及肠道菌群结构、脑功能的变化,观察穴位埋线对围绝经期女性肠道菌群、脑功能改变的影响。进一步应用超声引导比较不同组织层次埋线对中心性肥胖的改善作用。 |
||||||||||||||||||||||
|
Objectives of Study: |
In this study, a sham acupoint catgut embedding combined with lifestyle intervention group is used as the control, and the intervention of acupoint catgut embedding is applied to perimenopausal women with central obesity to observe changes in body weight, body mass index (BMI), waist circumference, hip circumference, waist-to-hip ratio, waist-to-height ratio, as well as related blood indicators, and the structure of the gut microbiota and brain function before and after treatment. The aim is to observe the effects of acupoint catgut embedding on the changes in gut microbiota and brain function in perimenopausal women. This study aims to investigate the potential benefits of acupoint catgut embedding in managing central obesity in perimenopausal women, with a focus on both anthropometric measurements and physiological parameters, as well as the underlying mechanisms related to gut microbiota and brain function alterations. Further apply ultrasonic guidance to compare the improvement effects of thread embedding at different tissue levels on central obesity. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1)继发性肥胖:下丘脑综合征、垂体腺瘤、库欣综合征、甲状腺功能减退症、胰岛素瘤、多囊卵巢综合征;2)子宫或卵巢异常,或经历过子宫切除术或卵巢切除术,以及处于妊娠期或哺乳期;3)伴有甲状腺功能亢进症、糖尿病、恶性肿瘤、心脏、肝脏、肾脏、造血系统疾病,以及精神疾病和其他严重疾病;4)3个月内未使用抗生素、微生态调节剂及胃肠动力药;5)存在磁共振禁忌情况;6)依从性差,其他不适于穴位埋线治疗的情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1) Secondary obesity: Hypothalamic syndrome, pituitary adenomas, Cushing's syndrome, hypothyroidism, insulinoma, polycystic ovary syndrome;2) Abnormalities of the uterus or ovaries, or individuals who have undergone hysterectomy or oophorectomy, as well as those who are pregnant or breastfeeding; 3) Comorbidities including hyperthyroidism, diabetes, malignant tumors, heart disease, liver disease, kidney disease, hematopoietic system disorders, mental illnesses, and other severe diseases; 4) No use of antibiotics, probiotics, or gastrointestinal motility drugs within the past 3 months; 5) Contraindications for magnetic resonance imaging (MRI); 6) Poor compliance, or other conditions not suitable for acupuncture and moxibustion treatment. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-01-01 00:00:00至 To 2024-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-03-07 00:00:00 至 To 2023-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采取SAS9.3统计分析软件程序产生随机数,按1:1比例随机分组,并根据随机分组编号按受试者就诊时间的先后顺序进行入组分配。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random number sequence by the statistician by a SAS9.3 statistical analysis software program according to the random numbers in proportion of 1:1 in order of hospitalization time. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
我们将努力确保参与者接受类似的治疗措施。所有负责数据记录的研究人员和统计学家都将对我们其他研究中的随机状态设盲。 |
|
Blinding: |
We will try to ensure that participants accept comparable treatment measures. All researchers and statisticians responsible for data recording will be blind to random states referring to our other research |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
试验完成后6个月时,在本网站详细描述试验结果,粘贴发表文章。若需要提供原始数据,可通过邮箱来信要求。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Six months after the completion of the test, the test results shall be described in detail on this website, and articles shall be pasted and published. If you need to provide original data, you can se |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表和原始数据采用临床试验公共管理平台进行记录和管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The case record form and original data are recorded and managed by the clinical trial public management platform |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |